↓ Skip to main content

Recent advances in migraine therapy

Overview of attention for article published in SpringerPlus, May 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

twitter
7 tweeters
facebook
1 Facebook page
wikipedia
1 Wikipedia page
googleplus
1 Google+ user

Citations

dimensions_citation
57 Dimensions

Readers on

mendeley
188 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Recent advances in migraine therapy
Published in
SpringerPlus, May 2016
DOI 10.1186/s40064-016-2211-8
Pubmed ID
Authors

Fabio Antonaci, Natascia Ghiotto, Shizheng Wu, Ennio Pucci, Alfredo Costa

Abstract

Migraine is a common and highly disabling neurological disorder associated with a high socioeconomic burden. Effective migraine management depends on adequate patient education: to avoid unrealistic expectations, the condition must be carefully explained to the patient soon as it is diagnosed. The range of available acute treatments has increased over time. At present, abortive migraine therapy can be classed as specific (ergot derivatives and triptans) or non-specific (analgesics and non-steroidal anti-inflammatory drugs). Even though acute symptomatic therapy can be optimised, migraine continues to be a chronic and potentially progressive condition. In addition to the drugs officially approved for migraine prevention by international governmental regulatory agencies, numerous different agents are commonly used for this indication, showing various levels of evidence of efficacy and tolerability. Guidelines published in recent years, based on evidence-based medicine data on migraine prophylaxis, are a useful source of guidance, especially for primary care physicians and neurologists without specific expertise in headache medicine. Although the field of pharmacological migraine prevention has seen few advances in recent years, potential novel approaches are now being developed. This review looks at emerging pharmacological strategies for acute and preventive migraine treatment that are nearing or have already entered the clinical trial phase. Specifically, it discusses preclinical and clinical data on compounds acting on calcitonin gene-related peptide or its receptor, the serotonin 5-HT1F receptor, nitric oxide synthase, and acid-sensing ion channel blockers.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 188 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Peru 1 <1%
Brazil 1 <1%
Unknown 185 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 30 16%
Student > Bachelor 27 14%
Other 26 14%
Researcher 20 11%
Student > Ph. D. Student 15 8%
Other 40 21%
Unknown 30 16%
Readers by discipline Count As %
Medicine and Dentistry 53 28%
Pharmacology, Toxicology and Pharmaceutical Science 31 16%
Neuroscience 18 10%
Biochemistry, Genetics and Molecular Biology 14 7%
Nursing and Health Professions 12 6%
Other 23 12%
Unknown 37 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 March 2020.
All research outputs
#2,076,213
of 15,835,365 outputs
Outputs from SpringerPlus
#160
of 1,795 outputs
Outputs of similar age
#45,770
of 266,347 outputs
Outputs of similar age from SpringerPlus
#1
of 21 outputs
Altmetric has tracked 15,835,365 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,795 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,347 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.